178 related articles for article (PubMed ID: 36336856)
1. Characterization of the Intestinal Microbiome in Healthy Adults over Sars-Cov-2 Vaccination.
Jiao J; Shen Y; Wang P; Zuo K; Yang X; Chen M; Dong Y; Li J
Front Biosci (Landmark Ed); 2022 Oct; 27(10):280. PubMed ID: 36336856
[TBL] [Abstract][Full Text] [Related]
2. Alterations of Fecal Metabolome Associated with BBIBP-CorV Vaccines against the SARS-CoV-2 Virus.
Dong Y; Shen Y; Wang P; Jiao J; Chen M; Li J
Front Biosci (Landmark Ed); 2023 Apr; 28(4):65. PubMed ID: 37114533
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X
Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349
[TBL] [Abstract][Full Text] [Related]
4. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B
Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
[TBL] [Abstract][Full Text] [Related]
6. BBIBP-CorV Vaccination against the SARS-CoV-2 Virus Affects the Gut Microbiome.
Shen Y; Dong Y; Jiao J; Wang P; Chen M; Li J
Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243047
[TBL] [Abstract][Full Text] [Related]
7. Altered T-cell receptor β repertoire in adults with SARS CoV-2 inactivated vaccine of BBIBP-CorV.
Quan Z; Qi A; Ma S; Li Y; Chen H; Yu X; Dong T; Li K; Qiu Y
Mol Immunol; 2023 Oct; 162():54-63. PubMed ID: 37647774
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing.
Tong R; Luo L; Zhao Y; Sun M; Li R; Zhong J; Chen Y; Hu L; Li Z; Shi J; Lyu Y; Hu L; Guo X; Liu Q; Shuang T; Zhang C; Yuan A; Sun L; Zhang Z; Qian K; Chen L; Lin W; Chen AF; Wang F; Pu J
Emerg Microbes Infect; 2023 Dec; 12(1):e2187245. PubMed ID: 36987861
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
Front Immunol; 2022; 13():967051. PubMed ID: 36159863
[TBL] [Abstract][Full Text] [Related]
10. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.
Badano MN; Sabbione F; Keitelman I; Pereson M; Aloisi N; Colado A; Ramos MV; Ortiz Wilczyñski JM; Pozner RG; Castillo L; Wigdorovitz G; E de Bracco MM; Fink S; Chuit R; Baré P
Mol Immunol; 2022 Mar; 143():94-99. PubMed ID: 35091231
[TBL] [Abstract][Full Text] [Related]
11. Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine.
Tang B; Tang L; He W; Jiang X; Hu C; Li Y; Zhang Y; Pang K; Lei Y; Li S; Liu S; Wang S; Yang M; Li Z; Zhao F; Yang S
Cell Rep Med; 2022 Oct; 3(10):100752. PubMed ID: 36228621
[TBL] [Abstract][Full Text] [Related]
12. The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults.
Wang Q; Ning J; Chen Y; Li B; Shi L; He T; Zhang F; Chen X; Zhai A; Wu C
Front Microbiol; 2022; 13():1008420. PubMed ID: 36406456
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia.
Petrović V; Vuković V; Patić A; Marković M; Ristić M
PLoS One; 2022; 17(2):e0263468. PubMed ID: 35108321
[TBL] [Abstract][Full Text] [Related]
14. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
[TBL] [Abstract][Full Text] [Related]
16. Immunodominant SARS-CoV-2-specific CD4
Ning J; Wang Q; Chen Y; He T; Zhang F; Chen X; Shi L; Zhai A; Li B; Wu C
J Med Virol; 2023 Apr; 95(4):e28743. PubMed ID: 37185843
[TBL] [Abstract][Full Text] [Related]
17. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.
Mahmoud S; Ganesan S; Al Kaabi N; Naik S; Elavalli S; Gopinath P; Ali AM; Bazzi L; Warren K; Zaher WA; Hosani FA
J Clin Virol; 2022 Jun; 150-151():105161. PubMed ID: 35439702
[TBL] [Abstract][Full Text] [Related]
18. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
Park S; Gatchalian KK; Oh H
Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
[TBL] [Abstract][Full Text] [Related]
19. Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine.
Mahmoud S; Ganesan S; Sharif-Askari NS; Cantarutti F; Wilson H; Ogrodzki P; Halwani R; Alkaabi N; Zaher WA
Curr Med Res Opin; 2022 Dec; 38(12):2069-2075. PubMed ID: 36274640
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
